Tofacitinib versus methotrexate in rheumatoid arthritis

New England Journal of Medicine

Volumn 370, Issue 25, 2014, Pages 2377-2386

  Lee, Eun Bong ^a   Fleischmann, Roy ^b   Hall, Stephen ^c   Wilkinson, Bethanie ^d   Bradley, John D ^d   Gruben, David ^d   Koncz, Tamas ^d   Krishnaswami, Sriram ^d   Wallenstein, Gene V ^d   Zang, Chuanbo ^d   Zwillich, Samuel H ^d   Van Vollenhoven, Ronald F ^e  

^a Seoul National University College of Medicine   (South Korea)

^b METROPLEX CLINICAL RESEARCH CENTER   (United States)

^c MONASH UNIVERSITY   (Australia)

^d PFIZER INC   (United States)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; TOFACITINIB;

ABSENCE OF SIDE EFFECTS; ADRENAL CORTEX ADENOMA; ADULT; ARTICLE; BRONCHITIS; BURKITT LYMPHOMA; CAUSE OF DEATH; CHICKENPOX; CHOLESTEROL BLOOD LEVEL; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DENGUE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ERYSIPELAS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GASTROENTERITIS; GASTROINTESTINAL INFECTION; HEART FAILURE; HEPATITIS C; HERPES ZOSTER; HUMAN; INFECTION; LOWER RESPIRATORY TRACT INFECTION; LUNG INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOTOR DYSFUNCTION; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; PAIN ASSESSMENT; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; RISK ASSESSMENT; SCORING SYSTEM; SEPSIS; SHARP SCORE; SIALOADENITIS; SIDE EFFECT; SKIN ABSCESS; STOMACH CANCER; SUDDEN CARDIAC DEATH; TONSILLITIS; TUBERCULOSIS;

ADMINISTRATION, ORAL; ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHOLESTEROL; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HERPES ZOSTER; HUMANS; JANUS KINASE 3; MALE; METHOTREXATE; MIDDLE AGED; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES;

EID: 84902593564     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1310476     Document Type: Article

References (32)

1. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004;350:2591-602.
2. Singh JA, Furst DE, Bharat A, et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-39.
3. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69:964-75. [Erratum, Ann Rheum Dis 2011;70:1519.]
4. van der Heijde D, Klareskog L, Singh A, et al. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial. Ann Rheum Dis 2006;65:328-34. (Pubitemid 43268221)
5. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43. (Pubitemid 39488667)
6. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7. [Erratum, Ann Rheum Dis 2011;70:1519.]
7. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;372:375-82.
8. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37. (Pubitemid 43122183)
9. Maradit-Kremers H, Nicola PJ, Crowson CS, O'Fallon WM, Gabriel SE. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis. J Rheumatol 2006;33:248-55. (Pubitemid 43209299)
10. Weinblatt ME, Schiff M, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum 2013;65:28-38.
11. Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 2011;70:39-46.
12. Meyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 2010;7:41.
13. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495-507.
14. van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508-19. [Erratum, N Engl J Med 2013;369:293.]
15. Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690, 550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013;381:451-60.
16. Kremer J, Li ZG, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 2013;159:253-61.
17. van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013;65:559-70.
18. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
19. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000;27:261-3.
20. van der Heijde D, Simon L, Smolen J, et al. How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion. Arthritis Rheum 2002;47:215-8. (Pubitemid 34303850)
21. Bruynesteyn K, van der Heijde D, Boers M, et al. Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum 2002;46:913-20. (Pubitemid 34303802)
22. Emery P, Fleischmann R, van der Heijde D, et al. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum 2011;63:1200-10. [Erratum, Arthritis Rheum 2012;64:1045.]
23. Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009;68:1870-7.
24. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999;159:2542-50.
25. Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000;39:655-65. (Pubitemid 30459953)
26. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96.
27. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93. [Errata, N Engl J Med 2001;344:76, 240.] (Pubitemid 32162981)
28. Möttönen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet 1999;353:1568-73. (Pubitemid 29219206)
29. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995;333:137-41.
30. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50. (Pubitemid 34620189)
31. McInnes IB, Kim H-Y, Lee S-H, et al. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study. Ann Rheum Dis 2014;73:124-31.
32. Isaacs JD, Nduaka CI, Zuckerman A, et al. Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib (CP-690,550). Ann Rheum Dis 2012;71:Suppl:S672 abstract.